Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
CStone Pharmaceuticals
Astellas Pharma Inc
Mirati Therapeutics Inc.
Nanjing Leads Biolabs Co.,Ltd
HC Biopharma Inc.
Akeso
Merck Sharp & Dohme LLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Qilu Pharmaceutical Co., Ltd.
BeiGene
CStone Pharmaceuticals
Providence Health & Services
Shanghai Junshi Bioscience Co., Ltd.
Qilu Pharmaceutical Co., Ltd.
Sun Yat-sen University
Qilu Pharmaceutical Co., Ltd.
The First Affiliated Hospital of Zhengzhou University
Shanghai Henlius Biotech
ChineseAMS
Huabo Biopharm Co., Ltd.
Hoffmann-La Roche
National Cancer Centre, Singapore
Lumos Pharma
Columbia University
SuZhou Stainwei Biotech Inc.
Traws Pharma, Inc.
UNC Lineberger Comprehensive Cancer Center
Ziekenhuis Oost-Limburg
SCRI Development Innovations, LLC
Disphar International B.V.
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hospital Santa Marcelina
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Columbia University
Mayo Clinic
AstraZeneca
Case Comprehensive Cancer Center
City of Hope Medical Center
City of Hope Medical Center
City of Hope Medical Center
National Cancer Institute (NCI)